PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect

Phase 1

Completed

Conditions: Therapeutic Equivalency
Food

Interventions: Drug: Fesoterodine

First Posted Date: 2008-12-11

Last Posted Date: 2010-03-24

Lead Sponsor: Pfizer

Target Recruit Count: 108

Registration Number: NCT00807118

Locations: 🇯🇵
Pfizer Investigational Site, Shinjuku-ku, Tokyo, Japan

An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System

Phase 3

Terminated

Conditions: Fungemia
Neutropenia
Candidiasis

Interventions: Drug: Active Anidulafungin
Drug: Active Caspofungin

First Posted Date: 2008-12-10

Last Posted Date: 2012-12-20

Lead Sponsor: Pfizer

Target Recruit Count: 21

Registration Number: NCT00806351

Locations: 🇸🇰
Pfizer Investigational Site, Kosice, Slovakia

An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida

Phase 3

Terminated

Conditions: Candidiasis
Fungemia

Interventions: Drug: Active Caspofungin
Drug: Active anidulafungin

First Posted Date: 2008-12-10

Last Posted Date: 2013-08-01

Lead Sponsor: Pfizer

Target Recruit Count: 41

Registration Number: NCT00805740

Locations: 🇨🇭
Pfizer Investigational Site, Geneve 14, Switzerland

UK Study Assessing Flexible Dose Fesoterodine in Adults

Phase 4

Completed

Conditions: Urinary Bladder, Overactive

Interventions: Drug: Fesoterodine

First Posted Date: 2008-12-10

Last Posted Date: 2011-01-26

Lead Sponsor: Pfizer

Target Recruit Count: 331

Registration Number: NCT00806494

Locations: 🇬🇧
Pfizer Investigational Site, Swindon, United Kingdom

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV

Completed

Conditions: Candidemia
Other Forms of Candida Infections(Intra-abdominal Abscess, Peritonitis)

First Posted Date: 2008-12-05

Last Posted Date: 2018-11-21

Lead Sponsor: Pfizer

Target Recruit Count: 244

Registration Number: NCT00802854

Locations: 🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷
Dong-A University Medical Center (Dong-A University Hospital), Busen, Korea, Republic of
🇰🇷
Keimyung University Dongsan Medical Center (KUDMC), Daegu, Korea, Republic of

and more 7 locations

Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]-esreboxetine

First Posted Date: 2008-12-03

Last Posted Date: 2011-04-07

Lead Sponsor: Pfizer

Target Recruit Count: 4

Registration Number: NCT00800956

Locations: 🇺🇸
Pfizer Investigational Site, Tacoma, Washington, United States

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

Phase 1

Completed

Conditions: Endometriosis

Interventions: Drug: PF-02413873 100 mg QD
Drug: PF-02413873 Placebo
Drug: PF-02413873 1500 mg QD
Drug: PF-02413873 20 mg QD
Drug: PF-02413873 500 mg QD

First Posted Date: 2008-12-02

Last Posted Date: 2010-02-10

Lead Sponsor: Pfizer

Target Recruit Count: 42

Registration Number: NCT00800618

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body

Phase 1

Terminated

Conditions: Generalized Anxiety Disorder

Interventions: Drug: PD 0332334
Drug: cimetidine

First Posted Date: 2008-12-02

Last Posted Date: 2010-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00800280

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

Phase 1

Completed

Conditions: Overweight

Interventions: Drug: Placebo
Drug: PF-04620110

First Posted Date: 2008-11-27

Last Posted Date: 2009-07-20

Lead Sponsor: Pfizer

Target Recruit Count: 27

Registration Number: NCT00799006

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Rollover Protocol for Prior SU011248 Protocols

Not Applicable

Completed

Conditions: Solid Tumors

Interventions: Drug: Sunitinib

First Posted Date: 2008-11-26

Last Posted Date: 2013-01-21

Lead Sponsor: Pfizer

Target Recruit Count: 314

Registration Number: NCT00798889

Locations: 🇬🇧
Pfizer Investigational Site, Newcastle-Upon-Tyne, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy